Overview Lithium and Acetate for Canavan Disease Status: Withdrawn Trial end date: 2011-01-01 Target enrollment: Participant gender: Summary The aim of this study is to determine whether oral supplementation with lithium and acetate may improve the biological and clinical prognosis in patients with Canavan Disease. Phase: Phase 2 Details Lead Sponsor: Assistance Publique - Hôpitaux de ParisCollaborator: European Leukodystrophy AssociationTreatments: Lithium CarbonateTriacetin